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Quality improvement with platelet additive 
solution for safer out-of-group platelet 
transfusions
M. Tynuv and W.A. Flegel
oriGinal report
Isoagglutinins in the plasma of apheresis platelets are a 
concern. High titer anti-A and anti-B can cause severe hemolytic 
transfusion reactions. Our facility is testing donor plasma using 
the gel method to identify isoagglutinin titers exceeding 250. 
Platelet additive solution (PAS), recently introduced as a collec-
tion and storage solution, replaces approximately 65 percent 
of the plasma in a platelet component. We intended to confirm 
the effect of PAS on the isoagglutinin titers. We compared the 
isoagglutinin titers in donor plasma from EDTA-anticoagulated 
whole blood (without PAS) with the plasma in apheresis platelet 
components with PAS. Titers were determined in a buffered 
gel matrix test using serial twofold dilution steps. Among 100 
donors tested, 26 plasma samples exceeded a threshold titer of 
250; 25 were group O and only one was group B. When samples 
from these 26 platelet components with PAS were tested, only 
one group O donor exceeded the threshold titer. Samples from 
plasma components with PAS consistently showed a 50 percent 
decrease in titer compared with the donors’ plasma samples. In 
conclusion, nearly half of the group O donors tested exceeded 
a titer of 250. Only one apheresis platelet component with PAS 
exceeded this clinically applied threshold—a 96 percent decrease 
compared with the number of donor plasma samples without 
PAS. The implementation of PAS in apheresis platelet components 
prompted us to revise our component screening process, which 
then minimized component manipulation of out-of-group platelet 
transfusions. Immunohematology 2019;35:108–115.
Key Words: PAS, ABO-incompatible platelets, platelet 
transfusion, isoagglutinin titer
Introduction
Transfusion of ABO-incompatible platelet components 
is an accepted practice in many institutions.1–4 The AABB’s 
Standards for Blood Banks and Transfusion Services states: 
“The transfusion service shall have a policy concerning 
transfusion of components containing significant amounts 
of incompatible ABO antibodies or unexpected red cell 
antibodies.”5 This guideline can be implemented in many 
different ways, leading to a wide variety of hospital practices.6–9 
Among 3152 North American laboratories, 529 (16.8%) did 
not have such a policy in 2007,9 and the clinical relevance of 
ABO plasma incompatibility caused by platelet transfusions 
may sometimes be missed.
Providing ABO-compatible platelets to all recipients 
will avoid minor ABO mismatches, but this step may be 
impractical, however, as the supply of group AB, A, and B 
platelet components is limited. A hospital with a policy to 
transfuse ABO-compatible apheresis platelet components 
may, once the platelet inventory is consumed, switch to 
random components rather than delaying patient care. When 
a group O platelet component is soon to expire, whereas 
ABO-compatible platelets with longer shelf lives are available, 
financial and inventory management reasons may prevail and 
trump the preference to avoid a potential risk of hemolysis by 
out-of-group transfusions.10
One apheresis platelet component contains approximately 
210–275 mL plasma,11 which is most often considered 
harmless when diluted in the recipient’s total blood volume 
during transfusion. If the recipient is a secretor (80% of the 
population), the soluble A or B blood group substances in 
the recipient’s plasma can neutralize some anti-A or anti-B 
isoagglutinins in the donor’s plasma.12,13 This protection 
becomes ineffective, however, when the recipient is not a 
secretor or large amounts of anti-A and anti-B are involved.14 In 
the situation described, a single platelet component with a high 
isoagglutinin titer can be harmful,8,15–22 and even fatal,8,22–25 
similar to transfusion of multiple components involving 
large plasma volumes relative to body size. There were six 
fatalities reported to the U.S. Food and Drug Administration 
(FDA) from 2005 to 2015 due to ABO-incompatible platelet 
transfusions.26 Hence, the amount of incompatible plasma 
must be monitored and limited for patients in need of regular 
platelet transfusions and for children or other small patients. 
The amount of plasma in the platelet component can be 
reduced by washing or volume-reducing before transfusion. 
These types of  component modifications may require up to 
1 hour for processing, contain 15–33 percent fewer platelets 
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with potentially impaired function, and have an expiration of 
4 hours.27,28
There are complementary approaches to minimize the risk 
of a hemolytic transfusion reaction, such as screening platelet 
donors to determine titers of A and B isoagglutinins.29,30 Any 
component exceeding a set threshold is labeled and excluded 
from out-of-group transfusions, unless washed or volume-
reduced. All blood donor centers have access to donor whole 
blood specimens for isoagglutinin testing, whereas the majority 
of transfusion services receive only processed components. 
Platelet additive solution (PAS) used in the platelet collection 
process reduces the plasma retained in the collection bag and 
dilutes the isoagglutinins.31 According to the package insert for 
an FDA-approved PAS product, approximately 65 percent of 
plasma is removed during collection.32
Thresholds for the clinically relevant titer have been 
proposed in the United States for ABO-mismatched platelet 
transfusion, ranging from 20 to 500 depending on the testing 
method.33–41 Titers performed in tube or gel for both direct and 
indirect methods can differ considerably in absolute numbers 
but correlate strongly.4,42–45 Cooling et al.36 used titers 128–200 
in a buffered gel (direct agglutination) method as a cutoff and 
suggested an estimated 10–20 percent of all donors should be 
considered to have high titer isoagglutinins.
We initially applied a threshold of 150 in buffered gel with 
pooled A1 and B red blood cells (RBCs), resulting in 50 percent 
of donors being marked as having a high titer.45 The threshold 
was soon adjusted to 250, lowering our high-titer rate to 20 
percent. Since August 2009, we have screened all plasma from 
platelet donors with a threshold dilution of 1:250 in buffered 
gel cards, as clinically applied and published previously.45 
The testing was performed using the plasma of whole blood 
specimens collected from donors before donation. Platelet 
components from donors above the threshold titer are labeled. 
They are washed or volume-reduced before transfusion, unless 
transfused to ABO-compatible recipients. Approximately 
20 percent of our platelet collections were subject to these 
restrictions.45 Platelet components purchased from outside 
suppliers were not tested, however, since no donor specimen is 
available. The purchased components were washed or volume-
reduced for any out-of-group transfusion.
Since the implementation of PAS for all apheresis 
collections at our institution in January 2016, the isoagglutinin 
titer in the donor’s plasma no longer reflected the titer in the 
platelet component. In this quality improvement project, we 
aimed to show a significant reduction of isoagglutinin titers 
in platelet components with PAS compared with the plasma 




Samples from healthy volunteer platelet apheresis donors 
were collected as part of their routine assessment during 
donation. Whole blood (3 mL EDTA-anticoagulated) was 
collected from the diversion pouch, and the plasma was tested 
for isoagglutinin titers. No extra blood was drawn from donors 
for this study. The donor samples were randomly collected to 
reach a set number of group O, A, and B samples, determined 
in advance. Based on our previous published data,45 a sample 
size of 100 platelet components was reasoned to be adequate 
for this quality improvement project.
After apheresis collection (Amicus, Fresenius Kabi, Lake 
Zurich, IL), platelets were reconstituted in PAS (Intersol, 
Fresenius Kabi), and a specimen was obtained from the final 
platelet bag and transferred into an EDTA tube (3 mL). The 
donor plasma and platelet PAS samples were collected and 
delivered to the main laboratory within 8 hours of collection 
in a transport box maintaining a temperature of 20–24°C. 
Whole blood specimens were centrifuged (StatSpin Express; 
Beckman Coulter, Indianapolis, IN) to separate plasma from 
RBCs, and isoagglutinin titers were determined in the plasma. 
The majority of specimens were tested within 72 hours of 
collection; if testing was delayed, specimens were refrigerated 
at 1–8°C and tested within 7 days of collection.46
Titration
A standard twofold dilution series was tested28 for whole 
blood plasma specimens starting with 1:32 (20 µL plasma 
in 620 µL saline). For PAS specimens, the starting dilution 
was 1:16 (30 µL PAS plasma in 450 µL saline). The titer was 
determined as the highest dilution that produced a reaction 
grade of 1+. To avoid variation during testing, all testing 
was performed by one individual using a buffered gel matrix 
method with a 15-minute incubation at room temperature 
(MTS buffered card, Ortho, Raritan, NJ). Our institution had 
established a threshold cutoff for high titer isoagglutinin45 
using a mix of pooled RBCs, prepared with equal volumes 
of 0.8 percent A1 and 0.8 percent B RBCs (0.8% Affirmagen, 
Ortho). We further evaluated the isoagglutinin specificities by 
testing titers with commercial A1 and B RBCs separately.
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Effect of Pathogen-Reduction Technology in PAS 
Platelet Components
Titers were performed on 19 randomly chosen PAS platelet 
components before and after applying a pathogen-reduction 
technology (Intercept; Cerus, Concord, CA). During the 
pathogen-reduction process, 17.5 mL amotosalen solution was 
added to the platelet component, potentially further diluting 
the residual plasma. A specimen after pathogen reduction was 
obtained by taking a sample from the sample pouch attached 
to the platelet bag.
Obtaining a sample from a segment tubing, after gentle 
mixing of the platelet component and stripping of the tubing, 
is an alternate collection method if the sample pouch is 
unavailable. All components in this study had pouches; thus, 
no segment needed to be tested.
Statistics
The VassarStats Web site for statistical calculation 
(vassarstats.net) was used for the Wilcoxon tests.
Results 
In this quality improvement project, we determined 
the effect of PAS on isoagglutinin titers in apheresis platelet 
components treated with pathogen-reduction technology 
(PRT).
Isoagglutinin Titers in Plasma from Whole Blood 
(Before PAS) and Platelet Components (After PAS)
We tested 100 platelet donors (52 group O, 32 group A, 
and 16 group B) using pooled RBCs and found 26 donors 
with titers of 256 or greater in their plasma from whole blood 
(Fig. 1). The platelet components collected in PAS from the 
same 100 donors had titers of 128 or less, except one group O 
platelet component. The difference was statistically significant 
(p < 0.001, two-sided Wilcoxon test).
Because of the random-sampling process, two consecutive 
collections from five different donors were included in the study 
(four group O and one group A). In three donors, the plasma 
titers of two independent donation events were identical, and 
in two group O donors, the titers differed by one dilution step 
only.
Anti-A and Anti-B Titers in Group O Donors
For the 52 group O donors, we tested A and B isoagglu-
tinins separately (Table 1). The mean and median titers did 
not differ substantially between anti-A and anti-B in the 
buffer gel matrix  method. Six donors had both anti-A and 
anti-B exceeding the threshold of 250. The number of donors 
with titers exceeding 250 decreased considerably after PAS 
application, when only one donor with anti-A and another 
donor with anti-B remained (Table 1).
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Fig. 1 Isoagglutinin titers in plasma from whole blood (before PAS) and platelet products (after PAS). Out of the 100 donor plasma tested, the 
results for 85 donors with titers of 32 and greater are shown. Among the samples before PAS, 26 samples had titers exceeding the threshold 
of 250 (red dotted line). 25 of them were group O (gray); except 1, all group B (yellow) and group A (blue) were below this threshold. After 












































1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 81 83 8577 79
IMMUNOHEMATOLOGY, Volume 35, Number 3, 2019 111
Isoagglutinin titers in platelets with PAS
Anti-A and Anti-B Titers in Donors of Group B and 
Group A
Isoagglutinin titers in plasma from whole blood (before 
PAS) and platelet components (after PAS) were tested in the 32 
group A and 16 group B donors (Fig. 2). A reduction in titer by 
at least one dilution step (50%) occurred after PAS application 
in all specimens tested (Fig. 2). Frequently, a reduction by two 
dilution steps (75%) was observed.
Effect of PRT
We tested isoagglutinin titers in 19 apheresis platelet 
components with PAS, of which 9 had titers less than 16. All 
other titers in the remaining samples before and after PRT 
application were identical with a mean ± standard deviation of 
46.4 ± 34.9 (median 32, range 16–128, N = 10).
Discussion
In our set of 100 donors tested, we found only one apheresis 
platelet component with PAS exceeding our clinically applied 
threshold of titer 250, a 96 percent decrease. This finding was 
an important practical result for the clinical application of PAS 
platelets. The implementation of PAS improved the clinical 
management for out-of-group transfusions with apheresis 
platelet components.
PAS reduced the isoagglutinin titers by at least 50 percent 
in apheresis platelet components with PAS, which was an 
expected result, validated by this study. PAS should remove 
approximately two-thirds of donor plasma from the apheresis 
platelet component, as stated by the manufacturer. In fact, a 
50 percent decrease in isoagglutinin titers was observed in all 
platelet components after PAS was applied.
Weisberg et al.31 proposed PAS as a method to prevent 
hemolytic transfusion reactions by minor ABO-mismatched 
platelet transfusions. We agree, since our data support this 
recommendation. Even though PAS substantially reduced the 
number of platelet components exceeding the titer threshold, 
PAS cannot eliminate all risk, since there is no definitive data 
to suggest the minimum amount of incompatible plasma that 
can be safely given to any recipient. PAS is a great way to limit 
the amount of incompatible plasma transfused at one time, 
although patients receiving multiple out-of-group prophylactic 
platelet transfusions should still require guidelines to limit 
the volume of incompatible plasma that can be transfused 
over time. Hence, we continue to recommend screening for 
isoagglutinin titers exceeding an institution-defined threshold 
as a means to mitigate the risk posed by incompatible ABO 
antibodies in out-of-group platelet transfusions.
When we implemented PAS for all apheresis platelet 
collections, we concurrently started treating the platelet 
components with a PRT. This treatment may dilute the 
isoagglutinins a bit, but it is not designed to remove plasma 
from the platelet component. We found that the titers of 
samples from the component collection pouch, collected 
after PRT treatment, were identical to the titers before PRT 
treatment. Different from PAS, the PRT treatment hence had 
no or minimal effect on the remaining isoagglutinin titer in 
the platelet components with PAS. If the pouch is unavailable, 
a segment from the tubing of the platelet component could be 
used instead.
When implemented in 2009, we tested whole blood 
specimens of the donors collected onsite. In an abundance of 
precaution, all platelet components imported from suppliers 
were considered high titer and given to ABO-compatible 
recipients or washed. As a result of this quality improvement 
project, we introduced testing of samples drawn from all 
platelet components. This process is also a suitable option 
for purchased platelet components, because their donor 
blood specimens are usually unavailable to the transfusion 
service. Screening for high isoagglutinin titers on platelet 
components instead of plasma from whole blood specimens 
led to better component management, better platelet recovery, 
safer transfusion practice, and a testing protocol for platelets 
collected outside of one’s own facility.






Donors with titer 
>250 (N)
Titer
Donors with titer 
>250 (N)Mean ± SD Median Range Mean ± SD Median Range
Before 157 ± 175 128 <32–1024 14 156 ± 156 128 <32–512 16 52
After 45 ± 46 32 <16–256 1 49 ± 51 32 <16–256 1 52
PAS = platelet additive solution; SD = standard deviation.
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Isoagglutinin titers tend to be higher in multiparous 
women,47 those having a recent vaccination,48–50 or 
possibly donors taking probiotics,51 for which the exact 
mechanisms are yet to be determined. An increased risk for 
intravascular hemolysis was attributed to larger isoagglutinin 
concentrations in group O individuals.13,15–25,52 Therefore, the 
majority of our donors were selected to be group O (N = 52), 
which also prevailed among the samples with titers above the 
threshold (Figure 1). We noticed that out of these 26 donors 
(Figure 1), 21 were female, 5 were male, and the only group B 
M. Tynuv and W.A. Flegel
Fig. 2 Anti-A and anti-B among group B and A donors before and after use of platelet additive solution (PAS). Isoagglutinin titers were 
compared between donor plasma (before PAS) and the plasma in the apheresis platelet component (after PAS). The titers were obtained for 
16 group B donors and 32 group A donors with separate red blood cell suspensions for group B and group A. Titers of 16 or less (whole 
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donor exceeding the threshold was female (data not shown). 
Anti-A and anti-B had similar titers by mean, median, and 
number of high titer specimens (Table 1), possibly because 
of the donor population.53,54 The method of testing may have 
contributed36–38,42–45; however, separate titers for IgM versus 
IgG antibodies were not performed. In future studies, high-
titer isoagglutinins in the donor may be evaluated for their 
ability to activate complement and cause hemolysis in the 
recipient.
This quality improvement project led to the modification 
of our standard operating procedure, which now allows us to 
test a sample from the component bag rather than testing the 
donor’s plasma from a blood sample. Since the implementation 
of the new process, the number of washed platelet components 
due to high isoagglutinin titer was markedly reduced. In 
addition, all imported platelets can now be screened for high 
isoagglutinin titers.
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